Black Rock Inc. Neurocrine Biosciences Inc Call Options Transaction History
Black Rock Inc.
- $4.35 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding NBIX
# of Institutions
657Shares Held
102MCall Options Held
290KPut Options Held
214K-
Vanguard Group Inc Valley Forge, PA9.81MShares$1.44 Billion0.02% of portfolio
-
Dodge & Cox San Francisco, CA5.57MShares$816 Million0.42% of portfolio
-
State Street Corp Boston, MA4.47MShares$655 Million0.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.09MShares$453 Million0.04% of portfolio
-
Jpmorgan Chase & CO New York, NY2.67MShares$392 Million0.02% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $14B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...